VIVES is a multi-sector fund that invests in projects with a positive societal impact
CISSOID is the leader in high temperature semiconductor solutions, delivering standard products and custom solutions for power management, power conversion and signal conditioning in extreme...
ExeVir Bio is a clinical stage company harnessing its VHH technology platform to generate robust antiviral therapies providing broad protection against viral infections, including coronaviruses. It is...
Promethera Biosciences’ mission is to bring patients life-saving treatments to reduce the need for liver transplantation. The company is pioneering the development of cell-based therapies that provide...
Chris Buyse, Co founder and Managing Partner of Fund+ :
"Fund+ is impressed by the outstanding scientific achievements of our Belgian universities and therefore supports and invests in its innovative...
Georges Caron, past CEO Keemotion :
"VIVES supported us at the beginning of the project when the risk was at its maximum. We needed time to test some hypotheses and confront academic research with...
"It has been great to partner early on with VIVES fund. VIVES fund helped us to finance the company, challenged us in our thinking to push us further in our thinking, provided us with regular input,...
Louvain-la-Neuve, March 1, 2022 – VIVES today announced that AbbVie (NYSE: ABBV) has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie’s neuroscience portfolio.
Sunrise, a healthtech company founded in 2015 in Belgium, has just closed a €3.25 million fundraising round. Led by Kurma Partners, this round of financing, in which the Vives-IUF fund linked to
Mont Saint-Guibert, Belgium – October 28, 2021 – Novadip Biosciences, a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs,